Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks

Launched by UNIVERSITY OF MIAMI · Oct 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well a personalized treatment program called PRAISE can help people with obstructive sleep apnea (OSA) stick to their prescribed treatment plan using a machine called Positive Airway Pressure (PAP). The goal is to see if this adherence to treatment has any effects on biomarkers related to Alzheimer's disease and on the participants’ thinking abilities.

To be eligible for this trial, participants need to be between 60 and 85 years old, identify as African American, African, Caribbean, or black, and have a diagnosis of obstructive sleep apnea. They should also be reachable by phone and willing to share their medical information. Participants can expect to be part of a supportive program that aims to improve their sleep apnea treatment experience. It’s important to note that individuals with severe illnesses or cognitive impairments that might prevent them from participating, as well as those planning to move within the year, are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Self-reported race/ethnicity as African American, African, Caribbean or black
• • Ages 60-85 years
• • accessible by phone
• • OSA diagnosis
• • consent, including permission to release medical data
• Exclusion Criteria:
• • progressive illnesses in which disability or death is expected within 1 year
• • impaired cognitive/ functional ability precluding participation
• • intention to move within the year
• • and a family member currently enrolled.